Would you consider using anthracycline for treating a Stage I triple negative breast cancer in a patient with a baseline mildly reduced LVEF 50-55%?  

I'm going to assume this is the clinical stage, and the patient has not yet had surgery. In this arena, if the patient is a fit surgical candidate then there are those who might advocate for taking to surgery up front if they are otherwise healthy. In patients like this, you could have a look at the...

In contrast to the above responses, I generally avoid the use of either an anthracycline or TC (docetaxel and cyclophosphamide) in the treatment of stage I TNBC (including clinical stage I who, for whatever reason, we feel might benefit from neoadjuvant therapy). This is based on the results of the ...